. intolerance). Ibrutinib is The present gold standard therapy for people with relapsed/refractory disorder, determined by the outcome of a number of section I-III trials, 115–119 but this is also switching for 2 principal factors: (i) an ever-increasing proportion of sufferers currently get ibrutinib as frontline therapy; and (ii) a handful of c